Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of one systematic review/meta-analysis. ^[1]
• Specific Population Types: The majority of participants in the studies were female, aged 18 to 65 years, and were treated in outpatient settings such as private offices or day clinics. No additional subgroup-specific findings regarding effectiveness were reported in the studies, suggesting that the results may primarily apply to this demographic without noted distinctions based on other characteristics.
• Safety Profile Summary: OnabotulinumtoxinA-20 U and AbobotulinumtoxinA-50 U showed a higher incidence of major adverse events (AEs) compared to placebo, with OnabotulinumtoxinA-20 U reporting a Peto odds ratio of 3.62 (95% confidence interval (CI) 1.50 to 8.74) and AbobotulinumtoxinA-50 U a Peto odds ratio of 3.36 (95% CI 0.88 to 12.87); however, there was no difference in overall AEs for OnabotulinumtoxinA-20 U (relative risk (RR) 1.14, 95% CI 0.89 to 1.45). IncobotulinumtoxinA-20 U and DaxibotulinumtoxinA-40 U did not report major AEs, but DaxibotulinumtoxinA-40 U was associated with a significant increase in any AEs (RR 2.23, 95% CI 1.46 to 3.40).